HLS Therapeutics (TSX:HLS) Current Accrued Expense: C$0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:HLS HLS Therapeutics Inc TSX:HLS
68 GF Score
Price C$3.90
GF Value C$4.37
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is HLS Therapeutics Current Accrued Expense?

HLS Therapeutics TSX:HLS +0.78% 68 Current Accrued Expense is C$0.00 Mil as of Jun. 2026. GuruFocus rates TSX:HLS with a GF Score™ of 68/100 and a GF Value™ of C$4.37 (Modestly Undervalued). The stock has 4 warning signs investors should review.

HLS Therapeutics's Current Accrued Expense for the quarter that ended in Jun. 2026 was C$0.00 Mil.

HLS Therapeutics Current Accrued Expense Related Terms

HLS Therapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for HLS Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HLS Therapeutics Current Accrued Expense Chart

HLS Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

HLS Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSX:HLS
68GF Score
HLS Therapeutics Inc TSX:HLS
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HLS Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of C$0.00 Mil mean?
HLS Therapeutics (TSX:HLS) has a Current Accrued Expense of C$0.00 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on HLS Therapeutics and its competitors.
Is HLS Therapeutics' Current Accrued Expense too high?
HLS Therapeutics' current Current Accrued Expense is C$0.00 Mil. Overall, HLS Therapeutics has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does HLS Therapeutics' Current Accrued Expense compare to ZTS?
HLS Therapeutics' Current Accrued Expense of C$0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Drug Manufacturers company?
A good Current Accrued Expense depends on the Drug Manufacturers industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on HLS Therapeutics and its competitors. HLS Therapeutics's current Current Accrued Expense is C$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HLS Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, HLS Therapeutics (TSX:HLS) is currently considered Modestly Undervalued. The stock's GF Value™ is C$4.37, compared to a current price of C$3.90 — trading 10.8% below its estimated fair value. The current Current Accrued Expense is C$0.00 Mil. HLS Therapeutics' overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For HLS Therapeutics (TSX:HLS), the current Current Accrued Expense is C$0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HLS Therapeutics (TSX:HLS) Overvalued in 2026?

Based on GuruFocus' analysis, HLS Therapeutics stock appears to be undervalued. The current stock price of C$3.90 is trading 10.8% below its estimated GF Value™ of C$4.37. GuruFocus considers HLS Therapeutics to be Modestly Undervalued.

Key valuation signals for TSX:HLS:

  • Current Accrued Expense: C$0.00 Mil
  • GF Value™: C$4.37 vs. price of C$3.90 (10.8% below fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the TSX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HLS Therapeutics Business Description

Other Exchanges HLTRF:USA74D:Germany
Address 10 Carlson Court, Suite 701, Etobicoke, Toronto, ON, CAN, M9W 6L2
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company's products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of world, with the majority of its revenue generated from Canada.
68GF Score

Get the complete analysis for TSX:HLS

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$3.90
Price
C$4.37
GF Value